Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan (T-DXh) as Continued Neoadjuvant Therapy in HER2+ Breast Cancer
NCT07589699Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab rezetecan in HER2-positive breast cancer, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Total Pathological Complete Response at 12 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT07589699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07589699.